Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV
A Randomized Controlled Study Testing the Efficacy of Immunotherapies to Control Plasma HIV RNA Concentrations Upon Interruption of Highly Active Antiretroviral Therapy (HAART).
연구 개요
상세 설명
While the advent of highly active antiretroviral therapy (HAART) has contributed to the increasing control of HIV infection and viral replication, ultimate control of HIV infection will require the development of effective HIV-specific immunity in HIV infected individuals.
This trial will evaluate the use of the ALVAC vCP1452 vaccine in combination with IL-2 to increase HIV-specific immune responses in HIV infected patients. ALVAC vCP1452 vaccine is a recombinant canarypox HIV vaccine that is administered as a monthly intramuscular injection. The IL-2 is self administered as a daily subcutaneous injection at a low, non-toxic dose (2 million units).
Participants in this study are randomized to receive either ALVAC and IL-2 or placebo for the first 3 months of the study. During this time, participants will continue on their current antiretroviral medications and have monthly study visits. Study visits will include a brief medical interview and physical exam, administration of the vaccine, and blood tests. At the end of 3 months, participants will discontinue both their study medications (IL-2 and ALVAC or placebo) and their antiretroviral medications. This Diagnostic Treatment Interruption (DTI) will continue for a minimum of 3 months. During the DTI, participants will have weekly study visits in which viral and lymphocyte dynamics are monitored.
연구 유형
등록
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
New York
-
New York, New York, 미국, 10021
- NY Presbyterian Weill Cornell Medical Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria
- HIV infected
- Stable HAART, defined as two or more antiretroviral drugs in combination. Changes in drugs are allowed if for any reason other than virologic failure.
- CD4 cell count > 200 cells/ml for the 12 months prior to enrollment
- CD4 cell count >= 400 cells/ml on two successive occasions at least 14 days apart within 30 days of study entry
- HIV RNA < 2 million copies/ml, with suppression on HAART to < 50 copies/ml on two successive occasions at least 14 days apart within 30 days of entry
- Acceptable methods of contraception
Exclusion Criteria
- Current AIDS-defining illness
- Virologic failure (HIV RNA > 10,000 copies/ml) while receiving current HAART regimen
- Immunomodulating agents, including interleukins; antibodies reactive with lymphocytes, monocytes, or antigen presenting cells; and polyribonucleotides
- IL-2 therapy within 4 weeks of study entry
- Uncontrolled active cardiac, renal, pulmonary, hepatic, or CNS disease
- History of active malignancy requiring chemotherapy
- History of thyroid disease or autoimmune disorders, including asthma, inflammatory bowel disease, rheumatoid arthritis, and psoriasis
- Active infection with hepatitis B virus or hepatitis C virus
- Severe retinopathy due to diabetes, hypertension, CMV, or macular degeneration
- Serious infection or other serious medical illness that is potentially life threatening and requires systemic therapy and/or hospitalization within 14 days of study entry
- Substance abuse that will compromise the participant's ability to adhere to the study requirements
- Current alcohol use of more than 1 drink/day any time during 6 months prior to study entry. One drink is defined as 12 ounces of beer, 5 ounces of wine, or 1.25 ounces of hard liquor.
- History of allergy to eggs, IL-2, or other components of the vaccine or IL-2 formulation
- Pregnant or breast-feeding
- Professionals working in close contact with canaries (e.g., breeding farms, bird shops)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 요인 할당
- 마스킹: 하나의
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
|---|
|
Mean log10 viral load for each experimental group from the average of 5 values obtained during Weeks 21 to 25, corresponding to 8 to 12 weeks following the interruption of HAART
|
2차 결과 측정
결과 측정 |
|---|
|
Proportion of subjects who relapse during the first 12 weeks following cessation of HAART
|
|
length of time to the termination of Step II
|
|
changes in frequency, activation state, and HIV-specific functional capacity of T cells and NK cells in blood, as monitored by the expression of intracellular cytokines during the first 12 weeks after cessation of HAART
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Kendall A. Smith, MD, Weill Medical College of Cornell University
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 1R01AI051181-01A1 (미국 NIH 보조금/계약)
- 0900-397
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .